- Report
- March 2024
- 196 Pages
Global
From €3283EUR$3,374USD£2,812GBP
€3648EUR$3,749USD£3,125GBP
- Report
- March 2024
- 194 Pages
Global
From €3283EUR$3,374USD£2,812GBP
€3648EUR$3,749USD£3,125GBP
- Report
- January 2024
- 175 Pages
Global
From €4865EUR$5,000USD£4,168GBP
- Report
- January 2024
- 200 Pages
Global
From €4865EUR$5,000USD£4,168GBP
- Report
- January 2024
- 150 Pages
Global
From €4719EUR$4,850USD£4,043GBP
- Report
- April 2024
- 94 Pages
Global
From €5449EUR$5,600USD£4,668GBP
- Report
- February 2024
- 173 Pages
Global
From €3503EUR$3,600USD£3,001GBP
- Report
- August 2023
- 147 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1459EUR$1,500USD£1,250GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1216EUR$1,250USD£1,042GBP
- Report
- November 2023
- 180 Pages
Global
From €4768EUR$4,900USD£4,084GBP
- Report
- October 2023
- 182 Pages
Global
From €4768EUR$4,900USD£4,084GBP
- Report
- October 2019
- 90 Pages
Global
From €5789EUR$5,950USD£4,959GBP
- Report
- August 2022
- 105 Pages
Global
From €4622EUR$4,750USD£3,959GBP
- Report
- November 2020
- 225 Pages
Global
From €10698EUR$10,995USD£9,164GBP
- Report
- February 2020
- 231 Pages
Global
From €3503EUR$3,600USD£3,001GBP
- Drug Pipelines
- September 2020
- 96 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Drug Pipelines
- September 2018
- 64 Pages
Global
From €3405EUR$3,500USD£2,917GBP
- Report
- October 2023
- 77 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- January 2021
- 143 Pages
China, Global
From €3000EUR$3,303USD£2,660GBP
Lanreotide is a medication used to treat endocrine and metabolic disorders. It is a somatostatin analogue, which works by blocking the release of hormones from the pituitary gland. It is used to treat acromegaly, a condition caused by an overproduction of growth hormone, and neuroendocrine tumors, which are tumors that originate in the endocrine system. It is also used to treat carcinoid syndrome, a condition caused by the overproduction of serotonin.
Lanreotide is available in both injectable and capsule forms. The injectable form is administered subcutaneously, while the capsule form is taken orally. The medication is typically taken once or twice a day, depending on the condition being treated.
The lanreotide market is a growing one, with many companies offering the medication. Some of these companies include Novartis, Ipsen, and Teva Pharmaceuticals. Show Less Read more